Zlitni, Soumaya
Bishara, Alex
Moss, Eli L.
Tkachenko, Ekaterina
Kang, Joyce B.
Culver, Rebecca N.
Andermann, Tessa M.
Weng, Ziming
Wood, Christina
Handy, Christine
Ji, Hanlee P.
Batzoglou, Serafim
Bhatt, Ami S. http://orcid.org/0000-0001-8099-2975
Funding for this research was provided by:
Damon Runyon Cancer Research Foundation (n/a)
National Cancer Institute (K08 CA184420, P30 CA124435)
National Science Foundation (DGE-114747)
V Foundation for Cancer Research (n/a)
Be The Match Foundation (Amy Strelzer Manasevit Award)
National Human Genome Research Institute (SGTP/JIMB)
American Association for Cancer Research (AACR-AstraZeneca Lymphoma Research Fellowship)
School of Medicine, Stanford University (Dean's fellowship)
Article History
Received: 19 December 2019
Accepted: 11 May 2020
First Online: 29 May 2020
Ethics approval and consent to participate
: A hematopoietic cell transplantation patient was recruited at the Stanford Hospital Blood and Marrow Transplant Unit under an IRB-approved protocol (Protocol #8903; Principal Investigator: Dr. David Miklos, co-Investigator: Dr. Ami Bhatt). The research performed herein conformed to the principles of the Helsinki Declaration. Written informed consent was obtained from the study subject; specific written consent for the presentation of data within this study was not obtained as no images or videos of the study subject are included and an effort was made to provide only highly relevant, limited clinical data on this study subject. A comprehensive chart review was carried out to identify clinical features of the patient, duration and exposure to medications, and diet.
: Not applicable. Our manuscript does not include images or videos of the study subject or any other identifiable information was presented. Only highly relevant, limited clinical data on the study subject was presented in this work.
: S.B. is an employee and shareholder of Illumina, Inc. The remaining authors declare that they have no competing interests.